149 related articles for article (PubMed ID: 22366003)
1. [Construction and sequence analysis of recombinant HCV-1b replicon by replacing NS5A region].
Li J; Zhou B; Zhou Y; Zeng Y; Li W; Wang J; Zhang J; Zhang H; Liu S
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jan; 32(1):46-9. PubMed ID: 22366003
[TBL] [Abstract][Full Text] [Related]
2. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.
Bouzgarrou N; Hassen E; Mahfoudh W; Gabbouj S; Schvoerer E; Ben Yahia A; Ben Mami N; Triki H; Chouchane L
J Med Virol; 2009 Dec; 81(12):2021-8. PubMed ID: 19856481
[TBL] [Abstract][Full Text] [Related]
3. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.
El-Shamy A; Shoji I; Saito T; Watanabe H; Ide YH; Deng L; Kawata S; Hotta H
Microbiol Immunol; 2011 Jun; 55(6):418-26. PubMed ID: 21371092
[TBL] [Abstract][Full Text] [Related]
4. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
El-Shamy A; Shoji I; Kim SR; Ide Y; Imoto S; Deng L; Yoon S; Fujisawa T; Tani S; Yano Y; Seo Y; Azuma T; Hotta H
PLoS One; 2012; 7(2):e30513. PubMed ID: 22319571
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
[TBL] [Abstract][Full Text] [Related]
6. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.
Muñoz de Rueda P; Casado J; Patón R; Quintero D; Palacios A; Gila A; Quiles R; León J; Ruiz-Extremera A; Salmerón J
J Virol; 2008 Jul; 82(13):6644-53. PubMed ID: 18448540
[TBL] [Abstract][Full Text] [Related]
7. Is investigation of hepatitis C virus NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis?
Squadrito G; Raffa G; Restuccia T; Pollicino T; Brancatelli S; Raimondo G
J Viral Hepat; 2002 Sep; 9(5):360-9. PubMed ID: 12225331
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
[TBL] [Abstract][Full Text] [Related]
9. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity.
Duverlie G; Khorsi H; Castelain S; Jaillon O; Izopet J; Lunel F; Eb F; Penin F; Wychowski C
J Gen Virol; 1998 Jun; 79 ( Pt 6)():1373-81. PubMed ID: 9634077
[TBL] [Abstract][Full Text] [Related]
10. Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?
Macquillan GC; Niu X; Speers D; English S; Garas G; Harnett GB; Reed WD; Allan JE; Jeffrey GP
J Gastroenterol Hepatol; 2004 May; 19(5):551-7. PubMed ID: 15086599
[TBL] [Abstract][Full Text] [Related]
11. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.
Nousbaum J; Polyak SJ; Ray SC; Sullivan DG; Larson AM; Carithers RL; Gretch DR
J Virol; 2000 Oct; 74(19):9028-38. PubMed ID: 10982347
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients.
Bokharaei-Salim F; Keyvani H; Salehi-Vaziri M; Sadeghi F; Monavari SH; Mehrnoush L; Alavian SM
Arch Virol; 2014 Nov; 159(11):2893-9. PubMed ID: 25139545
[TBL] [Abstract][Full Text] [Related]
13. Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection.
Shen C; Hu T; Shen L; Gao L; Xie W; Zhang J
J Gastroenterol Hepatol; 2007 Nov; 22(11):1898-903. PubMed ID: 17914967
[TBL] [Abstract][Full Text] [Related]
14. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy.
El-Shamy A; Nagano-Fujii M; Sasase N; Imoto S; Kim SR; Hotta H
Hepatology; 2008 Jul; 48(1):38-47. PubMed ID: 18537193
[TBL] [Abstract][Full Text] [Related]
15. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.
Kumthip K; Pantip C; Chusri P; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
J Viral Hepat; 2011 Apr; 18(4):e117-25. PubMed ID: 20955493
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b.
Hofgärtner WT; Polyak SJ; Sullivan DG; Carithers RL; Gretch DR
J Med Virol; 1997 Oct; 53(2):118-26. PubMed ID: 9334922
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy.
El-Shamy A; Kim SR; Ide YH; Sasase N; Imoto S; Deng L; Shoji I; Hotta H
Intervirology; 2012; 55(1):1-11. PubMed ID: 21293098
[TBL] [Abstract][Full Text] [Related]
18. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.
Veillon P; Payan C; Le Guillou-Guillemette H; Gaudy C; Lunel F
World J Gastroenterol; 2007 Feb; 13(8):1195-203. PubMed ID: 17451199
[TBL] [Abstract][Full Text] [Related]
19. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
[TBL] [Abstract][Full Text] [Related]
20. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients.
El-Shamy A; Shoji I; El-Akel W; Bilasy SE; Deng L; El-Raziky M; Jiang DP; Esmat G; Hotta H
J Clin Microbiol; 2012 Dec; 50(12):3886-92. PubMed ID: 22993188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
